The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
The fresh capital will propel Cordance into its first-in-human clinical trial
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
Relmada expects to initiate its Phase 3 program in the first half of 2026
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Subscribe To Our Newsletter & Stay Updated